Italia - italiano - Ministero della Salute

zoetis italia s.r.l. - subnitrato di bismuto - subnitrato di bismuto - 2.6 grammo (i), subnitrato di bismuto - 2.6 g - various products for teats and udder

Italia - italiano - Ministero della Salute

norbrook laboratories (ireland) limited - subnitrato di bismuto - subnitrato di bismuto - 2.6 grammo (i), subnitrato di bismuto - 2.6 g - various products for teats and udder

Italia - italiano - Ministero della Salute

continental pharma-belgio - subnitrato di bismuto - subnitrato di bismuto - 65 percentuale volume/volume (% v/v), subnitrato di bismuto - 65 % v/v - various products for teats and udder

Italia - italiano - Ministero della Salute

univet ltd - subnitrato di bismuto - subnitrato di bismuto - nd - various products for teats and udder

Italia - italiano - Ministero della Salute

norbrook laboratories (ireland) limited - subnitrato di bismuto pesante - subnitrato di bismuto pesante - 2.6 grammo (i), subnitrato di bismuto - 2.6 g - various products for teats and udder

Italia - italiano - Ministero della Salute

fatro s.p.a. - subnitrato di bismuto pesante - topico - subnitrato di bismuto pesante - 2.6 grammo (i), subnitrato di bismuto, pesante 2,6 grammi/siringa - various products for teats and udder - bovini

Italia - italiano - Ministero della Salute

sumitomo chemical agro europe s.a.s. - bacillus thuringiensis subsp. kurstaki ceppi di staphylococcus aureus-351; - granulare idrodispersibile - 6.4 g i valori indicati sono per 100 g di prodotto. - insetticida

Italia - italiano - Ministero della Salute

proplan plant protection company s.l. - fosetyl-aluminium; - granulare idrodispersibile - 80.0 g i valori indicati sono per 100 g di prodotto. - fungicida

Italia - italiano - Ecolab

ecolab deutschland gmbh -

Unione Europea - italiano - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti per dermatiti, esclusi i corticosteroidi - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.